BCR: a new target in resistance mediated by BCR/ABL-315I?

Targeting BCR/ABL with Tyrosine kinase inhibitors (TKIs) is a proven concept for the treatment of Philadelphia chromosome-positive (Ph+) leukemias but the “gatekeeper” mutation T315I confers resistance against all approved TKIs, with the only exception of ponatinib, a multi-targeted kinase inhibitor...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Genes Cancer
Glavni autori: Haberbosch, Isabella, Rafiei, Anahita, Oancea, Claudia, Ottmann, Gerhart Oliver, Ruthardt, Martin, Mian, Afsar Ali
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2016
Teme:
Research Paper
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4773704/
https://ncbi.nlm.nih.gov/pubmed/27014420
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items